NewAmsterdam Pharma (NAMS) Projected to Announce Quarterly Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMS) is expected to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect NewAmsterdam Pharma to announce earnings of ($0.4949) per share and revenue of $7.54 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:30 AM ET.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $2.83 million. On average, analysts expect NewAmsterdam Pharma to post ($1.82) EPS for the current fiscal year and ($1.62) EPS for the next fiscal year.

NewAmsterdam Pharma Trading Up 5.0%

Shares of NAMS stock opened at $20.50 on Wednesday. The company has a market cap of $2.45 billion, a P/E ratio of -9.49 and a beta of 0.10. The firm has a fifty day moving average price of $23.29 and a 200 day moving average price of $30.03. NewAmsterdam Pharma has a 12 month low of $19.13 and a 12 month high of $42.21.

Analysts Set New Price Targets

NAMS has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, October 15th. BMO Capital Markets started coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They set an “outperform” rating and a $58.00 price target on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Royal Bank Of Canada decreased their price objective on shares of NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating for the company in a research note on Monday, October 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $52.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $48.90.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Kastelein sold 50,246 shares of the business’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $25.03, for a total value of $1,257,657.38. Following the transaction, the insider directly owned 69,302 shares of the company’s stock, valued at approximately $1,734,629.06. The trade was a 42.03% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael Davidson purchased 10,000 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were purchased at an average price of $22.65 per share, for a total transaction of $226,500.00. Following the completion of the purchase, the chief executive officer owned 792,923 shares of the company’s stock, valued at approximately $17,959,705.95. This trade represents a 1.28% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 176,846 shares of company stock worth $4,661,919 over the last 90 days. 12.74% of the stock is currently owned by insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma (NASDAQ: NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company’s primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.

NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.